Healthcare Industry News: Pozen
News Release - June 15, 2010
POZEN Announces Election of Neal F. Fowler to the Board of DirectorsCHAPEL HILL, N.C.--(HSMN NewsFeed)--Pozen Inc. (NASDAQ: POZN ), today announced the election of Neal F. Fowler to its Board of Directors at the Annual Meeting of Shareholders held on June 10, 2010. Mr. Fowler is Chief Executive Officer of Liquidia Technologies, Inc. Mr. Fowler joined Liquidia in 2008 after seven successful years at Johnson & Johnson (J&J). While at J&J, Mr. Fowler served as President of Centocor, Inc., a multi-billion dollar subsidiary focused on development and commercialization of industry leading biomedicines used in the treatment of chronic inflammatory diseases. At Centocor, Mr. Fowler prepared the company for the launch of two potential blockbuster products and continued the company's legacy of double-digit growth for their flagship product REMICADE® (infliximab). Prior to Centocor, Mr. Fowler was President of Ortho-McNeil Neurologics Inc. and Vice President of the central nervous system franchise at Ortho-McNeil Pharmaceuticals. Mr. Fowler joined J&J after a successful 13-year career at Eli Lilly and Company, where he doubled sales of the cardiovascular business unit over a three-year period. Mr. Fowler is a native of Raleigh, NC and received a Bachelor of Science degree in Pharmacy and Masters of Business Administration from the University of North Carolina at Chapel Hill.
Dr. John R. Plachetka, POZEN’s Chairman, President and Chief Executive Officer said, “We are pleased to welcome Neal to the Pozen Board of Directors. His years of pharmaceutical experience will not only compliment, but will also expand the strength and capabilities of our board.”
Pozen Inc., headquartered in Chapel Hill, NC, is a pharmaceutical company committed to transforming medicine that transforms lives. Since its founding in 1996, Pozen has successfully created novel pharmacologic agents primarily for pain and pain-related conditions by combining existing drug therapies that result in superior patient outcomes. Moving forward, Pozen is poised to become a model 21st Century pharmaceutical company dedicated to ensuring that they produce cost-effective, evidence-based medicines; take a fresh approach to sales, marketing and medical education; and deliver high-quality, affordable pharmaceuticals to their customers.
The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For more detailed company information, including copies of this and other press releases, please visit: www.pozen.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.